Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07816432
PHASE2

A Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy

Sponsor: Longbio Pharma (Suzhou) Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, open-label Phase II clinical study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity profiles of LP-003 injection in participants with Wheat dependent exercise induced anaphylaxis. Its primary objective is to explore and preliminarily evaluate the efficacy of LP-003 Injection in the participants with Wheat dependent exercise induced anaphylaxis, as well as to investigate its safety, pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.

Official title: A Multicenter, Randomized, Open-Label Phase II Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat Allergy

Key Details

Gender

All

Age Range

12 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-09-04

Completion Date

2027-10-15

Last Updated

2026-09-11

Healthy Volunteers

No

Interventions

BIOLOGICAL

LP-003 Injection

s.c. injection, Q8W

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China